Monday, 8 June 2020

Global Anti-viral drugs Market 2020 – Investment Strategy, Outlook and Key Development till 2023

Market Scenario:
The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.
The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug market growth.
The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.
However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period. 
Key Players
MRFR have enlisted some of the prominent Anti-viral drugs Market Companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and  Astra Zeneca AB. 
Market Segmentation:
Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Regional Analysis:
Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market. 

No comments:

Post a Comment